The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
Encouraging early detection and breaking the silence around men’s health
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Subscribe To Our Newsletter & Stay Updated